Lexaria Bioscience (LEXX) Receivables (2016 - 2025)
Historic Receivables for Lexaria Bioscience (LEXX) over the last 14 years, with Q4 2025 value amounting to $152057.0.
- Lexaria Bioscience's Receivables fell 5357.11% to $152057.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $152057.0, marking a year-over-year decrease of 5357.11%. This contributed to the annual value of $432371.0 for FY2025, which is 17989.34% up from last year.
- Per Lexaria Bioscience's latest filing, its Receivables stood at $152057.0 for Q4 2025, which was down 5357.11% from $432371.0 recorded in Q3 2025.
- Lexaria Bioscience's Receivables' 5-year high stood at $954097.0 during Q2 2021, with a 5-year trough of $136796.0 in Q1 2023.
- Its 5-year average for Receivables is $348937.4, with a median of $329335.5 in 2024.
- Its Receivables has fluctuated over the past 5 years, first surged by 27568.79% in 2021, then plummeted by 8376.81% in 2022.
- Lexaria Bioscience's Receivables (Quarter) stood at $461512.0 in 2021, then tumbled by 37.96% to $286322.0 in 2022, then soared by 86.76% to $534731.0 in 2023, then plummeted by 38.75% to $327505.0 in 2024, then crashed by 53.57% to $152057.0 in 2025.
- Its Receivables stands at $152057.0 for Q4 2025, versus $432371.0 for Q3 2025 and $358129.0 for Q2 2025.